{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:07:08Z","timestamp":1790089628069,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Optimal treatment following first-line immunotherapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study evaluated futibatinib, a pan-FGFR inhibitor, combined with pembrolizumab in previously treated patients with FGF19-expressing HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible patients were \u226518\u2009years old with advanced HCC, prior systemic therapy, Child-Pugh A-B7 liver function, ECOG 0-2, and FGF19 overexpression. Patients received futibatinib 20\u2009mg orally daily plus pembrolizumab 200\u2009mg intravenously every 3\u2009weeks. The primary endpoint was progression-free survival at 6\u2009months (PFS6). Secondary endpoints included overall survival (OS), objective response rate (ORR), quality of life, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between August 2021 and March 2024, 14 patients enrolled and 13 were evaluable. Median age was 72\u2009years (range, 60-87), 53.8% were male, 92.3% had Child-Pugh A liver function, and all had received prior immunotherapy. Median progression-free survival was 15\u2009weeks (95% CI, 9.0-NE), with a PFS6 rate of 23.1% (95% CI, 8.6-62.3%). ORR was 0% (95% CI, 0-24.7%), while stable disease was observed in 53.9% of patients. Median OS was 55.7\u2009weeks (95% CI, 47.3-NE). Grade \u22653 adverse events occurred in 69.2% of patients, and grade \u22654 adverse events in 15.4%. One grade 5 event (acute-on-chronic kidney injury) was deemed unrelated to treatment. Common adverse events included hyperphosphatemia, fatigue, diarrhea, elevated transaminases, dry eye, nail changes, rash, and oral mucositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC. Effective post-immunotherapy treatment strategies remain an unmet need.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag343","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:13:02Z","timestamp":1787670782000},"source":"Crossref","is-referenced-by-count":0,"title":["Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-6489","authenticated-orcid":false,"given":"Nguyen H","family":"Tran","sequence":"first","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-3014","authenticated-orcid":false,"given":"Mathias E","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaylene A","family":"McCue","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-8333","authenticated-orcid":false,"given":"Amit","family":"Mahipal","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-4034","authenticated-orcid":false,"given":"Wen Wee","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Cleveland Clinic Cancer Center , Cleveland, OH 44195,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-6296","authenticated-orcid":false,"given":"Hani M","family":"Babiker","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic , Jacksonville, FL 32224,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair","family":"Majeed","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic , Jacksonville, FL 32224,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8460-1257","authenticated-orcid":false,"given":"Thorvardur R","family":"Halfdanarson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-5040","authenticated-orcid":false,"given":"Robert R","family":"McWilliams","sequence":"additional","affiliation":[{"name":"OSF HealthCare Cancer Institute, Peoria, IL 61603, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-5833","authenticated-orcid":false,"given":"Zhaohui","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-367X","authenticated-orcid":false,"given":"Ryan","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-2103","authenticated-orcid":false,"given":"Lionel Aurelien","family":"Kankeu Fonkoua","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3899-1831","authenticated-orcid":false,"given":"Leslie","family":"Washburn","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8280-056X","authenticated-orcid":false,"given":"Caitlin","family":"Conboy","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8686-4867","authenticated-orcid":false,"given":"Rondell P","family":"Graham","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Torbenson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-5337","authenticated-orcid":false,"given":"Patrick","family":"Starlinger","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7590-558X","authenticated-orcid":false,"given":"Krishan R","family":"Jethwa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hallemeier","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Revzin","sequence":"additional","affiliation":[{"name":"Department of Physiology and Biomedical Engineering, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7804-2695","authenticated-orcid":false,"given":"Ajit H","family":"Goenka","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-1030","authenticated-orcid":false,"given":"Sudhakar K","family":"Venkatesh","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6931-242X","authenticated-orcid":false,"given":"Mohamad B","family":"Sonbol","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic , Phoenix, AZ 85054,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J","family":"Borad","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic , Phoenix, AZ 85054,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-1699","authenticated-orcid":false,"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic , Phoenix, AZ 85054,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J","family":"Gores","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-8574","authenticated-orcid":false,"given":"Lewis R","family":"Roberts","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3567-1328","authenticated-orcid":false,"given":"Julie K","family":"Heimbach","sequence":"additional","affiliation":[{"name":"Department of Surgery and Transplant, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-8735","authenticated-orcid":false,"given":"Fang-Shu","family":"Ou","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"2026092210521614300_oyag343-B1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026092210521614300_oyag343-B2","doi-asserted-by":"crossref","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"2026092210521614300_oyag343-B3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"JCO"},{"key":"2026092210521614300_oyag343-B4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"2026092210521614300_oyag343-B5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","article-title":"Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach","volume":"179","author":"Presta","year":"2017","journal-title":"Pharmacol Ther"},{"key":"2026092210521614300_oyag343-B6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening","volume":"19","author":"Sawey","year":"2011","journal-title":"Cancer Cell"},{"key":"2026092210521614300_oyag343-B7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/hep.26402","article-title":"Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma","volume":"58","author":"Wang","year":"2013","journal-title":"Hepatology"},{"key":"2026092210521614300_oyag343-B8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1006\/cyto.1999.0485","article-title":"FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4","volume":"11","author":"Xie","year":"1999","journal-title":"Cytokine"},{"key":"2026092210521614300_oyag343-B9","first-page":"1","article-title":"FGF19\/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib","volume":"36","author":"Gao","year":"2017","journal-title":"JExp Clin Cancer Res"},{"key":"2026092210521614300_oyag343-B10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/cells8010031","article-title":"Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies","volume":"8","author":"Lang","year":"2019","journal-title":"Cells"},{"key":"2026092210521614300_oyag343-B11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat Genet"},{"key":"2026092210521614300_oyag343-B12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki","year":"2014","journal-title":"Nat Genet"},{"key":"2026092210521614300_oyag343-B13","author":"Hoeflich","year":"2015"},{"key":"2026092210521614300_oyag343-B14","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol"},{"key":"2026092210521614300_oyag343-B15","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1074\/jbc.M109.068783","article-title":"FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation","volume":"285","author":"Wu","year":"2010","journal-title":"J Biol Chem"},{"key":"2026092210521614300_oyag343-B16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000488541","article-title":"Characterization of hepatocellular carcinoma patients with FGF19 amplification assessed by fluorescence in situ hybridization: a large cohort study","volume":"8","author":"Kang","year":"2019","journal-title":"Liver Cancer"},{"key":"2026092210521614300_oyag343-B17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-12-56","article-title":"Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma","volume":"12","author":"Miura","year":"2012","journal-title":"BMC Cancer"},{"key":"2026092210521614300_oyag343-B18","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov"},{"key":"2026092210521614300_oyag343-B19","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann Oncol"},{"key":"2026092210521614300_oyag343-B20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2026092210521614300_oyag343-B21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","article-title":"The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity","volume":"7","author":"Palakurthi","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2026092210521614300_oyag343-B22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026092210521614300_oyag343-B23","doi-asserted-by":"crossref","first-page":"115955","DOI":"10.1016\/j.biopha.2023.115955","article-title":"FGF19\/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1","volume":"170","author":"Guo","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2026092210521614300_oyag343-B24","doi-asserted-by":"crossref","first-page":"S1429","DOI":"10.1016\/j.annonc.2024.10.085","article-title":"64P FGF19 promotes hepatocellular carcinoma evasion of immune response by stabilizing PD-L1","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann of Oncol"},{"key":"2026092210521614300_oyag343-B25","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.58347\/tml.2023.1674f","article-title":"Futibatinib (lytgobi) for cholangiocarcinoma","volume":"65","year":"2023","journal-title":"Med Lett Drugs Ther"},{"key":"2026092210521614300_oyag343-B26","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70344","article-title":"Covalent drug discovery: progress against key targets, emerging strategies and lessons learnt","author":"Brown","year":"2026","journal-title":"Br J Pharmacol"},{"key":"2026092210521614300_oyag343-B27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/13543784.2021.1837774","article-title":"Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives","volume":"30","author":"Rizzo","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2026092210521614300_oyag343-B28","doi-asserted-by":"crossref","first-page":"e2208844119","DOI":"10.1073\/pnas.2208844119","article-title":"FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma","volume":"119","author":"Tao","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026092210521614300_oyag343-B29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov"},{"key":"2026092210521614300_oyag343-B30","doi-asserted-by":"crossref","first-page":"49091","DOI":"10.18632\/oncotarget.10077","article-title":"Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment","volume":"7","author":"Kaibori","year":"2016","journal-title":"Oncotarget"},{"key":"2026092210521614300_oyag343-B31","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jceh.2021.05.010","article-title":"Spontaneous rupture of hepatocellular carcinoma: new insights","volume":"12","author":"Obeidat","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"2026092210521614300_oyag343-B32","doi-asserted-by":"crossref","first-page":"848903","DOI":"10.3389\/fonc.2022.848903","article-title":"Ruptured hepatocellular carcinoma: current status of research","volume":"12","author":"Xia","year":"2022","journal-title":"Front Oncol"},{"key":"2026092210521614300_oyag343-B33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.cardfail.2024.10.264","article-title":"Late-onset pembrolizumab induced immune checkpoint mediated myocarditis","volume":"31","author":"Urioste","year":"2025","journal-title":"J Card Fail"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag343\/70784357\/oyag343.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag343\/70784357\/oyag343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag343\/70784357\/oyag343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:24Z","timestamp":1790088744000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag343\/8770362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag343","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,25]]},"article-number":"oyag343"}}